Trichloroethylene (TCE) pharmacokinetics have been studied in experimental animals and humans for over 30 years. Compartmental and physiologically based pharmacokinetic (PBPK) models have been developed for the uptake, distribution, and metabolism of TCE and the production, distribution, metabolism, and elimination of P450-mediated metabolites of TCE. TCE is readily taken up into systemic circulation by oral and inhalation routes of exposure and is rapidly metabolized by the hepatic P450 system and to a much lesser degree, by direct conjugation with glutathione. Recent PBPK models for TCE and its metabolites have focused on the major metabolic pathway for metabolism of TCE (P450-mediated metabolic pathway). This article briefly reviews selected published compartmental and PBPK models for TCE. Trichloroacetic acid (TCA) is considered a principle metabolite responsible for TCE-induced liver cancer in mice. Liver cancer in mice was considered a critical effect by the U.S. Environmental Protection Agency for deriving the current maximum contaminant level for TCE in water. In the literature both whole blood and plasma measurements of TCA are reported in mice and humans. To reduce confusion about disparately measured and model-predicted levels of TCA in plasma and whole blood, model-predicted outcomes are compared for first-generation (plasma) and second-generation (whole blood) PBPK models published by Fisher and colleagues. Qualitatively, animals and humans metabolize TCE in a similar fashion, producing the same metabolites. Quantitatively, PBPK models for TCE and its metabolites are important tools for providing dosimetry comparisons between experimental animals and humans. TCE PBPK models can be used today to aid in crafting scientifically sound public health decisions for TCE. Key words: chloral hydrate, dichloroacetic acid, human, metabolism, PBPK models, pharmacokinetics, rodents, trichloroacetic acid, trichloroethanol, trichloroethylene. 
published a 3-compartment human model to describe the systemic clearance of TCE from blood and the urinary excretion of metabolites (trichloroacetic acid [TCA] and trichloroethanol [TCOH] ). Pharmacokinetic data were collected from four male Japanese students who were exposed to 100 ppm of TCE for 4 hr. Fernandez et al. ( 2) published a 5-compartment human model based on controlled human exposures to TCE vapors for 8 hr ranging from 54 to 160 ppm. TCE in exhaled breath and the cumulative amount of TCA and TCOH excreted in urine were simulated with this 5-compartment model. Since the publication of these two human pharmacokinetic models for TCE, several animal and human pharmacokinetic models for TCE and its metabolites have been published.
Qualitatively, animals and humans handle the uptake, distribution, metabolism, and elimination of TCE in a similar fashion. This is a very appealing situation for animal-tohuman extrapolation of TCE dosimetry based on validated animal physiologically based pharmacokinetic (PBPK) models for TCE. Usually cost and ethical concerns limit the amount of pharmacokinetic data that may be obtained in human volunteers, placing the burden of PBPK model development on animal studies. In addition, animal toxicity studies are usually employed to assess the human health hazard potential of chemicals such as TCE. Several rodent and human PBPK models were published for TCE and in some cases these models were used in cancer and non-cancer risk predictions. Andersen et al. (3) collected pharmacokinetic data in rats and developed a 4-compartment PBPK model for TCE in rats. Metabolic capacity was estimated in the rats by predicting atmospheric loss ofTCE in a gas uptake chamber. This was a landmark physiological model for TCE because the nonlinear kinetic behavior of TCE was quantitatively described with MichaelisMenten metabolic parameters. This provided the ability for a PBPK model to predict TCE blood and tissue time courses over a wide range of exposure concentrations or doses, corresponding to flow-and capacity-limited metabolism of TCE. Dallas et al. (4) incorporated the metabolic parameter estimates published by Andersen et al. (3) in a 4-compartment PBPK rat model. Detailed kinetic time-course studies of exhaled breath and blood were conducted with rats. Bogen (5) was interested in using a PBPK model for TCE to predict human health risks associated with environmental exposure to TCE. He performed a kinetic analysis with TCE using simplified steady-state equations to predict human health risks for cancer based on the amount of TCE metabolized. At this time, the U.S. Environmental Protection Agency (U.S. EPA) released a risk assessment for TCE that relied on the estimated amounts ofTCE metabolized in animal and human studies (6) . Koizumi (7) also predicted human health risks at steady state using a 4-compartment PBPK model and simulated the amount of TCE metabolized in rats and humans. Koizumi collected a limited amount of kinetic data for consumption of TCE dissolved in water.
More elaborate rodent PBPK models for TCE were developed to include TCA, a major metabolite of TCE. Understanding the dosimetry of TCA was thought important because of emerging animal toxicity findings with TCA stemming from identification of TCA as a byproduct of water chlorination. Fisher et al. (8, 9) collected pharmacokinetic data and developed PBPK pregnancy and lactation models to assess placental and lactational transfer of TCE (10) . TCA is a major metabolite of TCE and was thought by Fisher and colleagues to be the primary carcinogen responsible for TCE-induced liver tumors in mice, while DCA was a thought to be a very minor metabolite. First-generation PBPK models were developed for TCE and TCA in male and female mice (11, 12) and male and female rats (11) exposed to TCE vapors or dosed by gavage with TCE. Allen and Fisher (13) published a human PBPK model for TCE and TCA using previously published pharmacokinetic studies in humans with TCE and its metabolites. These models described TCE in blood of mice, rats, and humans; TCE in exhaled breath of humans; and TCA in plasma of mice, rats, and humans. These first-generation mice and human PBPK models for TCE and TCA will be discussed in detail.
The most recent advancements in PBPK modeling of TCE and its metabolites occurred in mice and humans (14) (15) (16) . In the mouse, pharmacokinetic studies were undertaken in the laboratory to support development and validation of second-generation PBPK models for P450-mediated metabolism of TCE to chloral hydrate (CH), DCA, TCA, TCOH, and trichloroethanol glucuronide (TCOH-b) (14, 15) . A human PBPK model was developed using new pharmacokinetic data collected from eight females and nine males that were exposed to TCE vapors (50 or 100 ppm) for 4 hr in a chamber (16) . Blood, urine, and limited exhaled breath samples were collected to support construction of this PBPK model for TCE, TCA, and TCOH (16) . These second-generation PBPK models will be discussed in detail.
Many of the toxic and carcinogenic properties of TCE result from metabolism ofTCE (6) . A key determinant in elucidating dose-response relationships for TCE is quantifying the pharmacokinetics of the major metabolites of TCE. The use of PBPK models in risk assessment is appealing because these models can be used to estimate targetorgan dose of metabolites in experimental animals and humans. Five (12) and Allen and Fisher (13) . Simon (20) (11, 12) were 4-compartment models, similar to styrene, reported by Ramsey and Andersen (21) . The four compartments included fat, liver, and slowly perfused (muscle) and richly perfused tissue groups (Figure 1) . TCE is extensively metabolized in the liver by P4502E1, yielding two major metabolites, TCA and TCOH. A simple, classical 1-compartment model was used to describe the kinetics of one metabolite, TCA. A proportionality constant (PO) was used to describe the stoichiometric yield of TCA based on the simulated amount of TCE that was metabolized ( Figure 1) . The differential equations used to describe the compartments are found in Fisher et al. (11) and Fisher and Allen (12) .
The second-generation PBPK models for TCE in male B6C3F, mice (14-16) were 6-compartment models consisting of fat, liver, kidney, lung, and slowly perfused (muscle) and richly perfused tissue groups ( Figure  2A ). In addition to the metabolite TCA, other P450-mediated metabolites (CH, DCA, TCOH, and TCOH-b) were included Inhalation p| Gas + Figure 1 . Schenatic of first-generation PBPK model for TCE and its oxidative metabolite in mice (11, 12) and humans ( 13 in the second-generation PBPK models. Each metabolite was described by a 4-compartment PBPK submodel ( Figure 2B ), which included the lung, liver, kidney, and the body. The liver was included in the submodel structure because of its role in metabolism and as a target organ for tumor formation in B6C3F1 mice after chronic oral administration of TCE (6) . The lung was included in the submodel structure because the lung is a target organ for tumor formation in B6C3F1 mice after chronic exposure to TCE vapors (22) . The kidney's role in the submodel structure was urinary excretion of metabolites and assessing metabolite dosimetry. The differential equations used to describe the submodel compartments are found in Abbas and Fisher (14) and Greenberg et al. (15) . The linkage of the metabolite submodels ( Figure 2C ) was based on a proposed pathway for metabolism of TCE taken from Davidson and Beliles (23) . The first metabolic step is oxidation of TCE and is the rate-limiting step in the metabolism of TCE. Subsequent rearrangement of TCE after insertion of the oxygen yields a reactive intermediate, trichloroacetaldehyde, which is then hydrolyzed to form CH. CH is either reduced by alcohol dehydrogenase and aldehyde reductase in the liver to TCOH or oxidized by aldehyde dehydrogenase in the liver to TCA. In the male B6C3F1 mouse, a small fraction of TCOH is converted to CH, presumably by alcohol dehydrogenase, and apparently a small fraction of TCA is dechlorinated in the liver to yield DCA. In male B6C3F1 mice, DCA is rapidly metabolized in the liver to nonchlorinated acids (oxalate, glyoxalate, and glycolate) and monochloroacetic acid (24) . The majority of free TCOH is conjugated with TCOH-b, which is excreted in urine and feces. The differential equations used to describe the compartments are found in Abbas and Fisher (14) and Greenberg et al. (15) .
A key difference between the first-and second-generation PBPK mice models for TCE and its oxidative metabolites was that PO values were not used to describe the yield of metabolites in the second-generation PBPK models. In the second-generation mouse model, all of the metabolized TCE was converted to CH at a rate equal to the rate of oxidation of TCE. First-order rate constants were then used to describe the metabolic conversion of CH->TCA, TCA-*DCA, TCOH--CH, and a saturable nonlinear term was used to describe TCOHR-TCOH-b. First-order terms were used to describe urinary excretion of CH, TCA, TCOH, and TCOH-b and fecal elimination ofTCOH-b.
Derivation of PBPK Model Parameters for Mice
Physiological values (e.g., blood flows and tissue and organ volumes) for the first-and second-generation PBPK model compartments were taken from the literature or calculated when organs or tissues were grouped as one compartment (Table 1) . Chemical-specific model parameters, such as partition coefficients (Table 2) , metabolic rate constants, and urinary excretion rate constants (Table 3) were determined experimentally in separate studies or by using pharmacokinetic timecourse data from experiments that were used to construct and validate the PBPK models. Fitted rate constant values were determined by Table 1 . Compartment volumes, blood flows, cardiac output, alveolar ventilation, and body weight values used in the first-and second-generation PBPK mice models for TCE. (Table 3) . This adjustment in Km value reflects the difficulty in describing TCE blood-time-course data for mice dosed by oral intubation with TCE dissolved in corn oil. There is no reason to suspect that corn oil alters the Km value for oxidation of TCE; rather this adjustment in Km reflects an oversimplification of the model structure for describing oral uptake of TCE dissolved in corn oil. In the first-generation PBPK model, TCE blood-time-course data for mice dosed with TCE dissolved in corn oil could not be described with a single oral uptake rate constant. In the second-generation PBPK model, TCE blood-time-course data were adequately described using two oral uptake rate constants representing both rapid and slow oral uptake phases ( (27) . Metabolic rate constant values for each administered metabolite were estimated by visual fitting of blood-time-course data for the administered chemical and its metabolic products using the submodel structure ( Figure 2B ) and metabolic pathway linkage ( Figure 2C) model with the same model structure as the first-generation PBPK model for mice (Figure 1) . TCA was described with a classical 1-compartment model similar to the mice. In the human, the yield of TCA was accounted for by conversion of TCOH to TCA and by conversion of TCE (via CH) to TCA, which was not explicitly determined in the first-generation mouse model. The human PBPK model for TCE and its oxidative metabolite, TCA, was developed using published human pharmacokinetic data taken from controlled TCE vapor exposures and studies in which sodium trichloroacetate was administered by i.v. drip and CH and TCOH by oral administration.
In the second-generation human model (16), six compartments (liver, lung, kidney, and richly perfused and slowly perfused tissues) were used to describe the pharmacokinetics of TCE (Figure 2A ). Only two metabolites of TCE, TCA and TCOH, were incorporated as submodels ( Figure 2D ) because TCA and TCOH were the only measured metabolites in blood except for intermittent trace amounts of DCA in plasma. Four compartments (body, liver, kidney, and lung) were used to describe these metabolites ( Figure 2B) . The TCE human model was linked to the submodels, as shown in Figure 2D . POs were used to describe the yield of TCA and TCOH, similar to the first-generation human PBPK model for TCA (Figure 1 ).
Derivation of PBPK Model Parameters for Humans
The first-generation model (13) was developed using pharmacokinetic data reported in the literature for humans. Simulations were conducted using SCoP software (National Biomedical Simulation Resource, Duke University, Durham, NC). The human V, value (14.9 mg/kg/hr) was an optimized value based on exhaled breath (TCE), TCE blood-time-course data, and TCA concentrations in plasma and urine.
The amount of TCOH produced from TCA was estimated by pharmacokinetic analysis using TCA plasma-time-course data from two volunteers given repeated oral administration of TCOH (31) . The volume of distribution of TCA was estimated by pharmacokinetic analysis of TCA plasma concentrations in three humans dosed with sodium TCA by i.v. drip (32) . Published controlled TCE vapor exposures in humans were used to develop and validate the human PBPK model for TCE using exhaled breath and blood concentration data.
The second-generation PBPK model for TCE in humans was based on recent 4-hr TCE inhalation exposures conducted with nine male and eight female consenting volunteers (16) . The whole-body exposures were conducted in a chamber described by Raymer et al. (33) . Several blood samples were taken from each individual by venous catheter during the exposure period and for 18 hr postexposure in addition to urine samples. Alveolar breath samples were collected from a few of the exposed volunteers after the 4-hr exposure using methods described by Pleil and Lindstrom (34) . After this period the volunteers returned to the Research Triangle Institute (Research Triangle Park, NC) once each day for 3 days to deliver their voided urine and to have blood drawn by venipuncture.
The following chemicals were analyzed for in blood and urine: TCE, CH, TCOH, TCOH-b, TCA, and DCA using methods reported by Abbas and Fisher (14) and by Ketcha et al. (35) . TCE, TCOH, and TCA were found in all blood samples, TCOH-b and TCA in all urine samples, and TCE in exhaled breath samples. DCA was found intermittently above the limit of detection (> 4 pg/L) in the blood of three of nine males and two of eight females, ranging from 5 to 12 1ug/L.
Blood/air partition coefficient values for TCE in the second-generation model were determined by vial equilibration (25) for several of the male and female volunteers (Table  4) . Human tissue/air PC values for TCE were determined for lung, liver, kidney, and fat using fresh chilled tissues from donors. Other donors provided liver, kidney, muscle, and lung tissue to measure TCOH and TCA PC values in tissues. Tissue/media and blood/ media PC values for TCOH and TCA were determined via a nonvolatile technique (26) . Fresh blood was obtained from two female donors to measure the TCOH and TCA blood/media PC values.
Using the model structure in Figure 2A and physiological model parameter values given in Table 5, the optimized values for Vm.,c, (mg/kg/hr, allometrically scaled, bw075) and Km (mg/L) were obtained for each gender by fitting predicted with observed mixed venous TCE blood concentrations (Table 6) . To obtain adequate model predictions of TCA and TCOH blood-time-course kinetics, the optimized Vmaxc values were increased from 2.30 and 4.74 mg/kg/hr for males and to 4.0 and 5.0 mg/kg/hr for females, respectively; Km values were set to the optimized of 1.80 and 1.66, respectively. The PO constant values for TCOH and TCA were set to 0.9 and 0.1 in males and females. That is, 90% of the oxidized TCE was converted to TCOH and 10 % to TCA. A large fraction of the TCOH is converted to TCA in humans (31) , presumably via back conversion of TCOH to CH. This back conversion of TCOH to TCA was described as a first-order process (Table 6) .
Urinary excretion of TCA and TCOH-b was variable between volunteers. This suggests that individual variability may exist in the initial metabolic step for TCE (P450 CYP2E1-mediated oxidation) or in the metabolic steps required for the formation and metabolism of its major metabolites. In addition, urinary excretion rates of the metabolites may vary between individuals. The pharmacokinetic determinants responsible for the observed variability in urinary excretion of metabolites are unknown at this time. Therefore, for the sake of simplicity, individual variability was characterized by adjusting only urinary excretion model parameters for TCOH and TCA. For each individual a fitted first-order urinary excretion rate constant was used to describe urinary excretion of TCA (Table 6) . A composite, nonlinear, Michaelis-Menten velocity term was used to collectively describe glucuronidation of TCOH and urinary excretion of TCOH-b (Table 6 ).
Ability of the PBPK Models to Predict Pharmacokinetics of TCE and Its Metabolites in Humans
The ability of the human model to simulate the pharmacokinetics of TCE and its metabolites is briefly discussed. Exhaled breath concentrations of TCE were not adequately predicted by either the first-or secondgeneration human PBPK models. Exhaled breath concentrations dropped more rapidly than were predicted immediately after cessation of vapor exposure to TCE. In the firstgeneration model for the adult male, Allen and Fisher (13) obtained good agreement between model-predicted (or -fitted) and mean observed TCE concentrations in blood and TCA concentrations in plasma and the mean cumulative amount of TCA excreted in urine for volunteers exposed to TCE vapors. In the second-generation PBPK model for male and female adults (16) , pharmacokinetic profiles for TCE and its metabolites were available for each individual. Gender-specific and individual-specific model predictions (or fits) of TCE, TCOH, and TCA in blood were in general agreement with observed data for individuals exposed to 100 ppm TCE. TCE blood concentrations were underpredicted by a factor of 2 for individuals exposed to 50 ppm TCE.
Comparison of First-and Second-Generation PBPK Models in Mice and Humans: Dosimetry of TCA Because of the importance of TCA as a proposed ultimate carcinogen for TCE-induced liver tumors in mice, a comparison of the TCA dosimetry and model sensitivity is presented for model-predicted TCA plasma and whole-blood levels. TCA was measured in plasma for the first-generation models and in whole blood for the second-generation PBPK models. The reason for the disparity between first-and second-generation mice and human model-predicted TCA concentrations in plasma and blood, respectively, is that TCA plasma and whole-blood measurements can differ by at least 2-fold because of uptake of TCA into red blood cells (32) .
The first-and second-generation PBPK models for male adults and male mice were compared by presenting simulation results for TCA in plasma and whole blood for a 4-hr 100-ppm vapor exposure to TCE. The human male model simulated eight individual males (16) . Daily area-under-the-concentration curve (AUC) values for TCA in plasma or blood in humans were calculated from a 10-day simulation period. In addition, the first-and second-generation PBPK models for gavage dosing of TCE were compared by simulating TCA in plasma and whole blood for a 400-mg/kg TCE single dose.
In humans the predicted peak concentration of TCA in plasma (first-generation model) was greater than the predicted peak TCA concentration in blood (second-generation model) (Figure 3) . The TCA plasma AUC value using the first-generation PKPK model was 367 mg/L/day and for the second-generation model, the blood TCA-AUC values (n = 8) ranged from 74 to 343 mg/L/day with a mean plasma value of 222 mg/L/day (Table 7) .
With this TCE exposure scenario, the most sensitive first-generation human model parameter for predicting AUC for TCA in plasma was the fractional yield of TCA from TCE (0.33, Table 6 ). A 5% increase in this value resulted in a 4.2% increase in the TCA plasma AUC value. When all other model parameter values were individually increased by 5%, the percent change in the TCA plasma AUC was negligible. In the second-generation human PBPK model the most sensitive model parameter for predicting AUC for TCA in blood was the body (muscle)/air partition coefficient value for TCA (0.52, Table 4 ). A 5% increase in this value resulted in a 3.6% decrease in the TCA blood AUC value. Other model parameters in the second-generation PBPK model were not as sensitive for predicting AUC for TCA in blood.
In male B6G3F, mice, the first-generation model-predicted peak TCA plasma concentrations were higher than the secondgeneration model-predicted TCA blood 
